Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Henry Schein Inc Market Cap
The Henry Schein Inc (HSIC) share price is expected to increase by 2.89% over the next year. This is based on calculating the average 12-month share price estimate provided by 16 stock analysts who have covered HSIC. Price targets range from $55 at the low end to $83 at the high end. The current analyst consensus for HSIC is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Henry Schein Inc has a total of 16 Wall St Analyst ratings. There are 9 buy ratings, 7 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Henry Schein Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of HSIC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Michael Petusky Barrington Research | Outperform | $82 | Maintains | Sep 20, 2024 |
| Rachel Vatnsdal JP Morgan | Overweight | $80 | Maintains | Aug 12, 2024 |
| Ross Muken Evercore ISI Group | In-Line | $70 | Maintains | Aug 7, 2024 |
| Kevin Caliendo UBS | Neutral | $72 | Maintains | Aug 7, 2024 |
| Jeff Johnson Baird | Outperform | $82 | Maintains | Aug 7, 2024 |
| Michael Petusky Barrington Research | Outperform | $82 | Maintains | Aug 7, 2024 |
| Jeff Johnson Baird | Outperform | $92 | Upgrade | Jul 22, 2024 |
| Ross Muken Evercore ISI Group | In-Line | $72 | Maintains | Jul 9, 2024 |
| Michael Petusky Barrington Research | Outperform | $92 | Maintains | Jul 5, 2024 |
| Jason Bednar Piper Sandler | Overweight | $86 | Reiterates | Jun 21, 2024 |
| Kevin Caliendo UBS | Neutral | $80 | Maintains | May 8, 2024 |
| Michael Petusky Barrington Research | Outperform | $92 | Maintains | May 8, 2024 |
| Brandon Couillard Jefferies | Hold | $81 | Maintains | Mar 6, 2024 |
| Rachel Vatnsdal JP Morgan | Overweight | $88 | Maintains | Mar 6, 2024 |
| Ross Muken Evercore ISI Group | In-Line | $83 | Maintains | Feb 28, 2024 |
| Michael Petusky Barrington Research | Outperform | $90 | Maintains | Feb 28, 2024 |
| Michael Cherny Leerink Partners | Market Perform | $78 | Initiates | Feb 26, 2024 |
| Jason Bednar Piper Sandler | Overweight | $86 | Maintains | Feb 26, 2024 |
| Rachel Vatnsdal JP Morgan | Overweight | $82 | Upgrade | Dec 12, 2023 |
| Jonathan Block Stifel | Buy | $75 | Reiterates | Nov 27, 2023 |
When did it IPO
1995
Staff Count
26,000
Country
United States
Sector/Industry
Healthcare/Medical Distribution
CEO
Mr. Stanley M. Bergman
Market Cap
$8.94B
In 2023, HSIC generated $12.34B in revenue, which was a decrease of -2.44% from the previous year. This can be seen as a signal that HSIC's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 30 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Henry Schein, Inc. (Nasdaq: HSIC) reported that over 2,300 employees created nearly 23,000 hygiene kits for families with children facing medical challenges, as part of its “We Care Global Challenge.”
Why It Matters - Henry Schein's community initiative enhances its corporate image and fosters employee engagement, potentially attracting socially conscious investors and improving brand loyalty.
Wed, 25 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Henry Schein, Inc. has been named to FORTUNE® magazine's “Change the World” list for its innovative emergency preparedness strategy, highlighting its positive social impact in health care.
Why It Matters - Henry Schein's recognition on FORTUNE's "Change the World" list highlights its strong corporate social responsibility, potentially enhancing brand reputation and attracting socially conscious investors.
Thu, 26 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Henry Schein, Inc. launched the “Prepare to Care” initiative to enhance emergency preparedness by pre-positioning health care supplies and cash donations with relief partners.
Why It Matters - Henry Schein's new initiative enhances its brand reputation and could drive demand for its products, positively influencing future revenue and stock performance.
Thu, 26 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Henry Schein, Inc. has activated a 24/7 Customer Assistance Hotline for dentists and physicians in Florida affected by Hurricane Helene, offering support for operational and financial issues.
Why It Matters - Henry Schein's proactive support during Hurricane Helene may enhance customer loyalty and mitigate operational disruptions, potentially stabilizing revenue and minimizing losses in affected areas.
Tue, 24 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - CareQuest Innovation Partners, Colgate-Palmolive, Henry Schein, and PDS Health are collaborating to highlight the link between oral health and overall health.
Why It Matters - The partnership among CareQuest, Colgate-Palmolive, Henry Schein, and PDS Health highlights growing recognition of oral health's impact on overall health, potentially driving demand for related healthcare products and services.
Tue, 17 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Henry Schein has been appointed the exclusive distributor of Curodont for Dental Service Organizations, enhancing its product offerings in the dental sector.
Why It Matters - Henry Schein's exclusive distribution deal with Curodont could enhance revenue streams and market share, potentially benefiting stock performance and investor confidence in both companies.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
